Cited by 2,051Cancer Immunotherapy and BiomarkersImmunotherapy and Immune ResponsesT-cell and B-cell Immunology

The DOI matches its Crossref record.

Cancer Immunotherapy

Couzin-Frankel, Jennifer·2013·Science

Open this paper in CoChat — free account

Abstract

This year marks a turning point in cancer, as long-sought efforts to unleash the immune system against tumors are paying off—even if the future remains a question mark.

Integrity signals

Registry

Crossref · 10.1126/science.342.6165.1432

Cites

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Sorted by citations

Items 501–600 of 1,000

LAG3 (CD223) and autoimmunity: Emerging evidence
Hu, S., Liu, X., Li, T., Li, Z., & Hu, F. (2020) · Journal of Autoimmunity · doi:10.1016/j.jaut.2020.102504 · Cited by 53
Oncolytic viruses—immunotherapeutics on the rise
Keller, B. A., & Bell, J. C. (2016) · Journal of Molecular Medicine · doi:10.1007/s00109-016-1453-9 · Cited by 57
Blockade of programmed cell death protein 1 (PD-1) in Sézary syndrome reduces Th2 phenotype of non-tumoral T lymphocytes but may enhance tumor proliferation
Saulīte, I., Ignatova, D., Chang, Y., Fassnacht, C., Dimitriou, F., Varypataki, E. M., Anzengruber, F., Nägeli, M., Cozzio, A., Dummer, R., et al. (2020) · OncoImmunology · doi:10.1080/2162402x.2020.1738797 · Cited by 52
The MHC Class-I Transactivator NLRC5: Implications to Cancer Immunology and Potential Applications to Cancer Immunotherapy
Shukla, A., Cloutier, M., Santharam, M. A., Ramanathan, S., & Ilangumaran, S. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22041964 · Cited by 55
Cancer immunotherapy
Dhar, R., Seethy, A. A., Singh, S., Pethusamy, K., Srivastava, T. P., Talukdar, J., Rath, G. K., & Karmakar, S. (2021) · Journal of Cancer Research and Therapeutics · doi:10.4103/jcrt.jcrt_1241_20 · Cited by 59
Novel immunotherapies for hematologic malignancies
Nelson, M. H., & Paulos, C. M. (2014) · Immunological Reviews · doi:10.1111/imr.12245 · Cited by 52
Regulatory T cells are not a strong predictor of survival for patients with glioblastoma
Thomas, A. A., Fisher, J. L., Rahme, G. J., Hampton, T. H., Baron, U., Olek, S., Schwachula, T., Rhodes, C. H., Gui, J., Tafe, L. J., et al. (2015) · Neuro-Oncology · doi:10.1093/neuonc/nou363 · Cited by 52
Antitumor vaccination of prostate cancer patients elicits PD-1/PD-L1 regulated antigen-specific immune responses
Rekoske, B. T., Olson, B. M., & McNeel, D. G. (2016) · OncoImmunology · doi:10.1080/2162402x.2016.1165377 · Cited by 52
“The field of cancer immunotherapy has seen remarkable growth and renewed momentum in the past few years due to many major successes, most notably the development and clinical success of Tcell checkpoint inhibitors.(1) Because tumor cells are derived from normal host cells, they can maintain or hijack autoimmunity defe…”
Background
Self-Assembling Peptide Epitopes as Novel Platform for Anticancer Vaccination
Rad‐Malekshahi, M., Fransen, M. F., Krawczyk, M., et al. (2017) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.6b01003 · Cited by 52
Bags versus flasks: a comparison of cell culture systems for the production of dendritic cell–based immunotherapies
Fekete, N., Béland, A. V., Campbell, K., Clark, S., & Hoesli, C. A. (2018) · Transfusion · doi:10.1111/trf.14621 · Cited by 52
Immunotherapy for pediatric brain tumors: past and present
Foster, J., Madsen, P. J., Hegde, M. G., Ahmed, N. M., Cole, K. A., Maris, J. M., Resnick, A. C., Storm, P. B., & Waanders, A. J. (2019) · Neuro-Oncology · doi:10.1093/neuonc/noz077 · Cited by 50
Nanobodies as non-invasive imaging tools
Rashidian, M., & Ploegh, H. L. (2020) · Immuno-Oncology Technology · doi:10.1016/j.iotech.2020.07.001 · Cited by 56
Breaking Bottlenecks for the TCR Therapy of Cancer
Gaissmaier, L., Elshiaty, M., & Christopoulos, P. (2020) · Cells · doi:10.3390/cells9092095 · Cited by 52
Biomaterials direct functional B cell response in a material-specific manner
Moore, E., Maestas, D. R., Cherry, C., Garcia, J. A., Comeau, H. Y., Huyer, L. D., Kelly, S. H., Peña, A. N., Blosser, R. L., Rosson, G. D., et al. (2021) · Science Advances · doi:10.1126/sciadv.abj5830 · Cited by 54
PD-L1 expression in EBV associated gastric cancer: a systematic review and meta-analysis
Lima, Á., de Sousa, H. M. L., Medeiros, R., Nobre, A., & Machado, M. (2022) · Discover Oncology · doi:10.1007/s12672-022-00479-0 · Cited by 51
SynNotch CAR-T cell, when synthetic biology and immunology meet again
Shirzadian, M., Moori, S., Rabbani, R., & Rahbarizadeh, F. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1545270 · Cited by 55
Bone Marrow Dendritic Cells Derived Microvesicles for Combinational Immunochemotherapy against Tumor
Wu, T., Qi, Y., Zhang, D., Song, Q., Yang, C., Hu, X., Bao, Y., Zhao, Y., & Zhang, Z. (2017) · Advanced Functional Materials · doi:10.1002/adfm.201703191 · Cited by 52
Autoimmune Myocarditis, Old Dogs and New Tricks.
Won, T., Song, E. J., Kalinoski, H. M., Moslehi, J. J., & Čiháková, D. (2024) · Circulation Research · doi:10.1161/circresaha.124.323816 · Cited by 51
Characterization of LAG-3, CTLA-4, and CD8+ TIL density and their joint influence on the prognosis of patients with esophageal squamous cell carcinoma
Wang, W., Chen, D., Zhao, Y., Zhao, T., Wen, J., Mao, Y., Chen, C., Sang, Y., Zhang, Y., & Chen, Y. (2019) · Annals of Translational Medicine · doi:10.21037/atm.2019.11.38 · Cited by 50
Anti-gastric cancer activity of cultivated Dendrobium huoshanense stem polysaccharide in tumor-bearing mice: Effects of molecular weight and O-acetyl group
Liu, B., Li, Q.-M., Shang, Z.-Z., et al. (2021) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2021.10.016 · Cited by 50
Pancreatic tumor eradication via selective Pin1 inhibition in cancer-associated fibroblasts and T lymphocytes engagement
Liu, J., Wang, Y., Mu, C., Li, M., Li, K., Li, S., Wu, W., Du, L., Zhang, X., Li, C., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-31928-7 · Cited by 51
Synergistic Cancer Therapies Enhanced by Nanoparticles: Advancing Nanomedicine Through Multimodal Strategies
Mousavi‐kiasary, S. M. S., Senabreh, A., Zandi, A., Pena, R., Cruz, F., Adibi, A., & Hooshmand, N. (2025) · Pharmaceutics · doi:10.3390/pharmaceutics17060682 · Cited by 56
Adjuvant Activity Enhanced by Cross-Linked CpG-Oligonucleotides in β-Glucan Nanogel and Its Antitumor Effect
Miyamoto, N., Mochizuki, S., Fujii, S., Yoshida, K., & Sakurai, K. (2016) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.6b00675 · Cited by 50
A dualistic model of primary anal canal adenocarcinoma with distinct cellular origins, etiologies, inflammatory microenvironments and mutational signatures: implications for personalised medicine
Herfs, M. F., Roncarati, P., Koopmansch, B., Peulen, O., Bruyère, D., Lebeau, A., Hendrick, E., Hubert, P., Poncin, A., Penny, W., et al. (2018) · British Journal of Cancer · doi:10.1038/s41416-018-0049-2 · Cited by 52
Mechanisms of checkpoint inhibition-induced adverse events
Urwyler, P., Earnshaw, I., Bermudez, M., Perucha, E., Wu, W., Ryan, S. E., Mcdonald, L., Karagiannis, S. N., Taams, L. S., Powell, N., et al. (2020) · Clinical & Experimental Immunology · doi:10.1111/cei.13421 · Cited by 48
Tumor microenvironment-activated therapeutic peptide-conjugated prodrug nanoparticles for enhanced tumor penetration and local T cell activation in the tumor microenvironment
Zhu, X., Li, C., Lu, Y., Liu, Y., Wan, D., Zhu, D., Pan, J., & Ma, G. (2020) · Acta Biomaterialia · doi:10.1016/j.actbio.2020.11.008 · Cited by 49
Injectable Hydrogel as a Unique Platform for Antitumor Therapy Targeting Immunosuppressive Tumor Microenvironment
Liu, Y., Geng, Y., Yue, B., Lo, P., Huang, J., & Jin, H. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2021.832942 · Cited by 50
Genetic Engineering and Enrichment of Human NK Cells for CAR-Enhanced Immunotherapy of Hematological Malignancies
Soldierer, M., Bister, A., Haist, C., Thivakaran, A., Cengiz, S. C., Sendker, S., Bartels, N., Thomitzek, A., Smorra, D., Hejazi, M., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.847008 · Cited by 49
MICA SNPs and the NKG2D system in virus-induced HCC
Goto, K., & Kato, N. (2014) · Journal of Gastroenterology · doi:10.1007/s00535-014-1000-9 · Cited by 52
Improving natural killer cell cancer immunotherapy
Berrien-Elliott, M. M., Romee, R., & Fehniger, T. A. (2015) · Current Opinion in Organ Transplantation · doi:10.1097/mot.0000000000000243 · Cited by 49
Medication overuse in oncology: current trends and future implications for patients and society
Schleicher, S. M., Bach, P. B., Matsoukas, K., & Korenstein, D. R. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30099-8 · Cited by 48
CRISPR therapeutic tools for complex genetic disorders and cancer (Review)
Baliou, S., Adamaki, M., Kyriakopoulos, A. M., Spandidos, D. A., Panayiotidis, M. I., Christodoulou, I., & Zoumpourlis, V. C. (2018) · International Journal of Oncology · doi:10.3892/ijo.2018.4434 · Cited by 55
“Finally, the CRISPR system has been employed in the modification of T cells, particularly with chimeric antigen receptor (CAR) or artificial TCRs, prior to introducing them into the body of cancer patients (95) (Fig.”
Current status of immunotherapy against gastrointestinal cancers and its biomarkers: Perspective for precision immunotherapy
Hazama, S., Tamada, K., Yamaguchi, Y., Kawakami, Y., & Nagano, H. (2018) · Annals of Gastroenterological Surgery · doi:10.1002/ags3.12180 · Cited by 50
Advances in Lipid-Based Nanoparticles for Cancer Chemoimmunotherapy
Wang, T., Suita, Y., Miriyala, S., Dean, J., Tapinos, N., & Shen, J. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13040520 · Cited by 50
“This situation was greatly improved when the pioneering checkpoint inhibitor ipilimumab, a monoclonal antibody (mAb) that targets CTLA4 (cytotoxic T-lymphocyte-associated protein 4), was approved for the treatment of advanced melanoma in 2011 by the FDA, which was featured by Science as the breakthrough of the year in…”
Charting roadmaps towards novel and safe synergistic immunotherapy combinations
Sanmamed, M. F., Berraondo, P., Rodriguez-Ruiz, M. E., & Melero, I. (2022) · Nature Cancer · doi:10.1038/s43018-022-00401-1 · Cited by 50
Nanobiomimetic Medicine
Chang, M., Dong, C., Huang, H., Ding, L., Feng, W., & Chen, Y. (2022) · Advanced Functional Materials · doi:10.1002/adfm.202204791 · Cited by 50
Synthetic biology approaches for improving the specificity and efficacy of cancer immunotherapy
Zhu, B., Yin, H., Zhang, D., Zhang, M., Chao, X., Scimeca, L., & Wu, M.-R. (2024) · Cellular and Molecular Immunology · doi:10.1038/s41423-024-01153-x · Cited by 50
No longer an untreatable disease: How targeted and immunotherapies have changed the management of melanoma patients
Girotti, M. R., Saturno, G., Lorigan, P. C., & Marais, R. (2014) · Molecular Oncology · doi:10.1016/j.molonc.2014.07.027 · Cited by 49
TCRs Genetically Linked to CD28 and CD3ε Do Not Mispair with Endogenous TCR Chains and Mediate Enhanced T Cell Persistence and Anti-Melanoma Activity
Govers, C., Sebestyén, Z., Roszik, J., van Brakel, M., Berrevoets, C., Szöőr, Á., Panoutsopoulou, K., Broertjes, M., Van, T., Vereb, G., et al. (2014) · The Journal of Immunology · doi:10.4049/jimmunol.1302074 · Cited by 47
Radiation-Induced Transformation of Immunoregulatory Networks in the Tumor Stroma
Martínez-Zubiaurre, I., Chalmers, A. J., & Hellevik, T. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.01679 · Cited by 52
“Int J Radiat Oncol Biol Phys (2016) 94(5):1173–80.”
BackgroundInfluential
ST2 as checkpoint target for colorectal cancer immunotherapy
der Jeught, K. V., Sun, Y., Fang, Y., Zhou, Z., Jiang, H., Yu, T., Yang, J., Kamocka, M. M., So, K. M., Li, Y., et al. (2020) · JCI Insight · doi:10.1172/jci.insight.136073 · Cited by 48
Advances in local and systemic drug delivery systems for post-surgical cancer treatment
Aquib, M., Juthi, A. Z., Farooq, M. A., Ali, M. G., Janabi, A. H. W., Bavi, S., Banerjee, P., Bhosale, R. B., Bavi, R., & Wang, B. (2020) · Journal of Materials Chemistry B · doi:10.1039/d0tb00987c · Cited by 51
Epithelial Ovarian Cancer and the Immune System: Biology, Interactions, Challenges and Potential Advances for Immunotherapy
Macpherson, A. M., Barry, S. C., Ricciardelli, C., & Oehler, M. K. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9092967 · Cited by 51
“, blocking immune suppressor signals such as CTLA-4 and PD-1, has been a powerful strategy for cancer immunotherapy [290].”
Background
Challenges and Opportunities in the Statistical Analysis of Multiplex Immunofluorescence Data
Wilson, C. M., Ospina, O. E., Townsend, M. K., Nguyen, J. V., Segura, C. M., Schildkraut, J. M., Tworoger, S. S., Peres, L. C., & Fridley, B. L. (2021) · Cancers · doi:10.3390/cancers13123031 · Cited by 53
“and have been revolutionary in the treatment of many cancers [3,4], including melanoma, lung cancer, and renal cell carcinoma [5].”
Background
Oncogene addiction as a foundation of targeted cancer therapy: The paradigm of the MET receptor tyrosine kinase
Orlando, E., Aebersold, D. M., Medová, M., & Zimmer, Y. (2018) · Cancer Letters · doi:10.1016/j.canlet.2018.12.001 · Cited by 46
Catalytic Nanoparticles in Biomedical Applications: Exploiting Advanced Nanozymes for Therapeutics and Diagnostics
Manoharan, D., Wang, L., Chen, Y., Li, W., & Yeh, C. (2024) · Advanced Healthcare Materials · doi:10.1002/adhm.202400746 · Cited by 50
Expanded Human Blood-Derived γδT Cells Display Potent Antigen-Presentation Functions
Khan, M. W. A., Curbishley, S. M., Chen, H., Thomas, A. D., Pircher, H., Mavilio, D., Steven, N. M., Eberl, M., & Moser, B. (2014) · Frontiers in Immunology · doi:10.3389/fimmu.2014.00344 · Cited by 50
Using the GEMM-ESC strategy to study gene function in mouse models
Huijbers, I. J., Bravo, J. D., Ali, R. B., Pritchard, C. E. J., Braumuller, T. M., van Miltenburg, M. H., Henneman, L., Michalak, E. M., Berns, A. J. M., & Jonkers, J. (2015) · Nature Protocols · doi:10.1038/nprot.2015.114 · Cited by 47
Exploiting IL-17-producing CD4+ and CD8+ T cells to improve cancer immunotherapy in the clinic
Majchrzak, K., Nelson, M. H., Bailey, S. R., Bowers, J. S., Yu, X., Rubinstein, M. P., Himes, R. A., & Paulos, C. M. (2016) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-016-1797-6 · Cited by 48
“These clinical examples are just some of the reasons why the journal Science Magazine selected cancer immunotherapy as the 2013 “Breakthrough of the Year” [8].”
Background
Translational nanoparticle engineering for cancer vaccines
Grippin, A., Sayour, E. J., & Mitchell, D. A. (2017) · OncoImmunology · doi:10.1080/2162402x.2017.1290036 · Cited by 47
“Cancer immunotherapy has recently produced significant advancements in treatment and is widely recognized as one of the major recent breakthroughs in clinical oncology.(2) Adoptive cellular therapies, involving the transfer of ex vivo expanded tumor-reactive lymphocytes, have produced substantial clinical responses in…”
Background
Immunotherapy of hepatocellular carcinoma using chimeric antigen receptors and bispecific antibodies
Hoseini, S. S., & Cheung, N. V. (2017) · Cancer Letters · doi:10.1016/j.canlet.2017.04.013 · Cited by 47
Effect of dendritic cell–based immunotherapy on hepatocellular carcinoma: A systematic review and meta-analysis
Chen, C., MA, Y.-H., Zhang, Y., Zhang, F., Zhou, N., Wang, X., LIU, T., & Li, Y. (2018) · Cytotherapy · doi:10.1016/j.jcyt.2018.06.002 · Cited by 47
Safety of Immune Checkpoint Inhibitors in Patients With Pre-Existing Inflammatory Bowel Disease and Microscopic Colitis
Grover, S., Ruan, A. B., Srivoleti, P. D., Giobbie‐Hurder, A., Braschi‐Amirfarzan, M., Srivastava, A., Buchbinder, E. I., Ott, P. A., Kehl, K. L., Awad, M. M., et al. (2020) · JCO Oncology Practice · doi:10.1200/jop.19.00672 · Cited by 48
Innate Immune Cells and Their Contribution to T-Cell-Based Immunotherapy
Ginefra, P., Lorusso, G., & Vannini, N. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21124441 · Cited by 48
Intravital Imaging of Adoptive T-Cell Morphology, Mobility and Trafficking Following Immune Checkpoint Inhibition in a Mouse Melanoma Model
Lau, D., Garçon, F., Chandra, A., Lechermann, L. M., Aloj, L., Chilvers, E. R., Corrie, P. G., Okkenhaug, K., & Gallagher, F. A. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01514 · Cited by 51
Choice of Nanovaccine Delivery Mode Has Profound Impacts on the Intralymph Node Spatiotemporal Distribution and Immunotherapy Efficacy
Wang, J., Wang, S., Ye, T., Li, F., Gao, X., Wang, Y., Ye, P., Qing, S., Wang, C., Yue, H., et al. (2020) · Advanced Science · doi:10.1002/advs.202001108 · Cited by 47
Microbiota Modulation of Myeloid Cells in Cancer Therapy
Goldszmid, R. S., Dzutsev, A., Viaud, S., Zitvogel, L., Restifo, N. P., & Trinchieri, G. (2015) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-14-0225 · Cited by 46
“The most successful approaches have utilized either adoptive T-cell transfer or inhibition of immune checkpoints, such as CTLA-4 andPD-1/PDL1/2, which free antitumor T cells from the immunologic brakes expressed by the tumor cells or by other cells in the tumor microenvironment (42, 46, 47).”
Nanoplatform Self‐Assembly from Small Molecules of Porphyrin Derivatives for NIR‐II Fluorescence Imaging Guided Photothermal‐Immunotherapy
Cao, Y., Wei, D., Yang, L., Luo, Z., Yu, P., Li, H., Zhang, C., Liu, X., Wu, F., Wu, M., et al. (2022) · Advanced Healthcare Materials · doi:10.1002/adhm.202102526 · Cited by 46
Cancer Immunotherapy and Delivery System: An Update
Yang, M. J., Olaoba, O. T., Zhang, C., Kimchi, E. T., Staveley-O’Carroll, K. F., & Li, G. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14081630 · Cited by 46
Hypoxia Reversion and STING Pathway Activation through Large Mesoporous Nanozyme for Near-Infrared-II Light Amplified Tumor Polymetallic-Immunotherapy
Qu, C. F., Shao, X., Jia, R., Song, G., Shi, D., Wang, H., Wang, J., & An, H. (2024) · ACS Nano · doi:10.1021/acsnano.4c05483 · Cited by 49
The New Era of Cancer Immunotherapy
Khalil, D. N., Budhu, S., Gasmi, B., Zappasodi, R., Hirschhorn-Cymerman, D., Plitt, T., Henau, O. D., Zamarin, D., Holmgaard, R., Murphy, J. T., et al. (2015) · Advances in cancer research · doi:10.1016/bs.acr.2015.04.010 · Cited by 46
Anti-HBV Drugs: Progress, Unmet Needs, and New Hope
Kang, L., Pan, J., Wu, J., Hu, J., Sun, Q., & Tang, J. Y. (2015) · Viruses · doi:10.3390/v7092854 · Cited by 45
“Therefore, based on oncological application (blocking agents) and the developing knowledge of immune checkpoint inhibitors, it is hoped that the application of certain blocking agents for treating chronic viral disease will not be too far in the future [89,95].”
Background
An Iron Oxide Nanocarrier Loaded with a Pt(IV) Prodrug and Immunostimulatory dsRNA for Combining Complementary Cancer Killing Effects
Hernández‐Gil, J., Cobaleda‐Siles, M., Zabaleta, A., Salassa, L., Calvo, J., & Rivas, J. C. M. (2015) · Advanced Healthcare Materials · doi:10.1002/adhm.201500080 · Cited by 46
Sustainable strategies for nano-in-micro particle engineering for pulmonary delivery
Silva, A. S., Tavares, M. T., & Aguiar‐Ricardo, A. (2014) · Journal of Nanoparticle Research · doi:10.1007/s11051-014-2602-0 · Cited by 45
“First pass metabolism may be avoided, and cancer, especially nonsmall lung cancer (one of the leading causes of death worldwide), may be effectively treated (Couzin-Frankel 2013).”
Background
The right touch: design of artificial antigen-presenting cells to stimulate the immune system
van der Weijden, J., Paulis, L. E. M., Verdoes, M., van Hest, J. C. M., & Figdor, C. G. (2014) · Chemical Science · doi:10.1039/c4sc01112k · Cited by 46
Cancer Immunotherapy Using γδT Cells: Dealing with Diversity
Scheper, W., Sebestyén, Z., & Kuball, J. H. E. (2014) · Frontiers in Immunology · doi:10.3389/fimmu.2014.00601 · Cited by 47
“What lessons can be learned from gammadelta T cell-based cancer immunotherapy trials? Cell Mol Immunol (2013) 10(1):35–41.”
Background
Immunotherapy for kidney cancer
Bedke, J., Stühler, V., Stenzl, A., et al. (2017) · Current Opinion in Urology · doi:10.1097/mou.0000000000000466 · Cited by 46
“Further research in immunooncology identified the programmed death-1 (PD-1) molecule as a major immune checkpoint molecule involved in peripheral tolerance and in the immune escape mechanisms [11].”
Background
Prediction of treatment responses to neoadjuvant chemotherapy in triple-negative breast cancer by analysis of immune checkpoint protein expression
Asano, Y., Kashiwagi, S., Goto, W., Takada, K., Takahashi, K., Morisaki, T., Fujita, H., Takashima, T., Tomita, S., Ohsawa, M., et al. (2018) · Journal of Translational Medicine · doi:10.1186/s12967-018-1458-y · Cited by 46
“Background Various immunosuppressive factors from cancer cells in the tumor microenvironment inhibit host immune responses to cancer [1, 2].”
Peptide Delivery Systems for Cancer Vaccines
He, X., Abrams, S. I., & Lovell, J. F. (2018) · Advanced Therapeutics · doi:10.1002/adtp.201800060 · Cited by 45
Oncolytic Viruses for Canine Cancer Treatment
Sánchez, D., Cesarman-Maus, G. N., Amador-Molina, A., et al. (2018) · Cancers · doi:10.3390/cancers10110404 · Cited by 46
Colorectal cancer: A paradigmatic model for cancer immunology and immunotherapy
Ijsselsteijn, M. E., Pamplona, R. S., Hermitte, F., & de Miranda, N. F. C. C. (2019) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2019.05.003 · Cited by 48
Single-cell protein profiling in microchambers with barcoded beads
Armbrecht, L., Müller, R. S., Nikoloff, J. M., et al. (2019) · Microsystems & Nanoengineering · doi:10.1038/s41378-019-0099-5 · Cited by 46
Immune receptor repertoires in pediatric and adult acute myeloid leukemia
Zhang, J., Hu, X. S., Wang, J., Sahu, A. D., Cohen, D., Song, L., Ouyang, Z., Fan, J., Wang, B., Fu, J., et al. (2019) · Genome Medicine · doi:10.1186/s13073-019-0681-3 · Cited by 48
Tumor microenvironment characterization in head and neck cancer identifies prognostic and immunotherapeutically relevant gene signatures
Huo, M., Zhang, Y., Chen, Z., Zhang, S., Bao, Y., & Li, T. (2020) · Scientific Reports · doi:10.1038/s41598-020-68074-3 · Cited by 47
Manipulation of PD‐L1 Endosomal Trafficking Promotes Anticancer Immunity
Ye, Z., Xiong, Y., Wang, P., Wei, W., Huang, L., Yue, J., Zhang, C., Lin, G., Huang, F., Zhang, L. N., et al. (2022) · Advanced Science · doi:10.1002/advs.202206411 · Cited by 46
Nanoparticles Targeting Lymph Nodes for Cancer Immunotherapy: Strategies and Influencing Factors
Li, Z., Zhong, N., Cao, L., Cai, Z., Xiao, Y., Wang, G.-R., Liu, B., Xu, C., & Bu, L. (2024) · Small · doi:10.1002/smll.202308731 · Cited by 48
Cancer pharmacogenomics, challenges in implementation, and patient-focused perspectives
Patel, J. N. (2016) · Pharmacogenomics and Personalized Medicine · doi:10.2147/pgpm.s62918 · Cited by 50
Near-infrared photoimmunotherapy: a comparison of light dosing schedules
Ogata, F., Nagaya, T., Nakamura, Y., Sato, K., Okuyama, S., Maruoka, Y., Choyke, P. L., & Kobayashi, H. (2017) · Oncotarget · doi:10.18632/oncotarget.17047 · Cited by 47
Accurate control of dual-receptor-engineered T cell activity through a bifunctional anti-angiogenic peptide
Zhang, E., Gu, J., Xue, J., Lin, C., Liu, C., Li, M., Hao, J., Setrerrahmane, S., Chi, X., Qi, W., et al. (2018) · Journal of Hematology & Oncology · doi:10.1186/s13045-018-0591-7 · Cited by 46
Checkpoints and beyond – Immunotherapy in colorectal cancer
Gutting, T., Burgermeister, E., Härtel, N., & Ebert, M. P. A. (2018) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2018.04.003 · Cited by 48
Programmable Molecular Scissors: Applications of a New Tool for Genome Editing in Biotech
Saha, S. K., Saikot, F. K., Rahman, M. S., Jamal, M. A. H. M., Rahman, S. M. K., Islam, S. M. R., & Kim, K. (2018) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2018.11.016 · Cited by 48
Local Intracerebral Immunomodulation Using Interleukin-Expressing Mesenchymal Stem Cells in Glioblastoma
Mohme, M., Maire, C. L., Geumann, U., Schliffke, S., Dührsen, L., Fita, K. D., Akyüz, N., Binder, M., Westphal, M., Guenther, C., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-0803 · Cited by 45
Bifunctional Naphthoquinone Aromatic Amide-Oxime Derivatives Exert Combined Immunotherapeutic and Antitumor Effects through Simultaneous Targeting of Indoleamine-2,3-dioxygenase and Signal Transducer and Activator of Transcription 3
Huang, R.-Z., Jing, X.-T., Huang, X., Pan, Y.-M., Fang, Y., Liang, G.-B., Liao, Z., Wang, H., Chen, Z., & Zhang, Y. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b01386 · Cited by 48
Immune Escape After Adoptive T-cell Therapy for Malignant Gliomas
Wildes, T. J., Dyson, K. A., Francis, C. P., Wummer, B. M., Yang, C., Yegorov, O., Shin, D. H., Grippin, A., Dean, B. D., Abraham, R. S., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-1065 · Cited by 46
“Introduction Immunotherapy has revolutionized cancer care (1, 2).”
Background
Reassessing Patterns of Response to Immunotherapy with PET: From Morphology to Metabolism
Costa, L. B., Queiroz, M. A., Barbosa, F. D. G., Nunes, R. F., Zaniboni, E. C., Ruiz, M. F. D. C. M., Jardim, D. L. F., Marin, J. F. G., Cerri, G. G., & Buchpiguel, C. A. (2020) · Radiographics · doi:10.1148/rg.2021200093 · Cited by 44
Mild cold‐stress depresses immune responses: Implications for cancer models involving laboratory mice
Messmer, M. N., Kokolus, K. M., Eng, J. W. ‐., Abrams, S. I., & Repasky, E. A. (2014) · BioEssays · doi:10.1002/bies.201400066 · Cited by 46
MRI techniques for immunotherapy monitoring
Lau, D., Corrie, P. G., & Gallagher, F. A. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-004708 · Cited by 44
Targeted localized use of therapeutic antibodies: a review of non-systemic, topical and oral applications
Jones, R. G. A., & Martino, A. C. (2015) · Critical Reviews in Biotechnology · doi:10.3109/07388551.2014.992388 · Cited by 43
“Complete therapy (4 courses) of Ipilimumab (Yervoy ) for the treatment of melanoma, for instance, costs $120 000 (Couzin-Frankel, 2013).”
BackgroundMethod
Cancer immunotherapy using novel tumor‐associated antigenic peptides identified by genome‐wide cDNA microarray analyses
Nishimura, Y., Tomita, Y., Yuno, A., et al. (2015) · Cancer Science · doi:10.1111/cas.12650 · Cited by 44
Targeting Immune Checkpoints in Hematologic Malignancies
Alatrash, G., Daver, N. G., & Mittendorf, E. A. (2016) · Pharmacological Reviews · doi:10.1124/pr.116.012682 · Cited by 46
“Immune checkpoint inhibition for the treatment of cancer is undoubtedly a great breakthrough in cancer therapy (Couzin-Frankel, 2013; Dizon et al., 2016).”
Background
Crk adaptor protein promotes PD-L1 expression, EMT and immune evasion in a murine model of triple-negative breast cancer
Kumar, S., Davra, V., Obr, A. E., Geng, K., Wood, T. L., Lorenzo, M. S. D., & Birge, R. B. (2017) · OncoImmunology · doi:10.1080/2162402x.2017.1376155 · Cited by 44
Recent Advances in Peptide-Based Approaches for Cancer Treatment
Conibear, A. C., Schmid, A., Kamalov, M., Becker, C. F. W., & Bello, C. (2017) · Current Medicinal Chemistry · doi:10.2174/0929867325666171123204851 · Cited by 44
Immunotherapy for pancreatic cancer: A long and hopeful journey
Xu, J., Wang, L., Cheng, Y., Zhang, G., Hu, S., Zhou, B., & Zhan, H. (2018) · Cancer Letters · doi:10.1016/j.canlet.2018.03.040 · Cited by 45
Double domain polyethylenimine-based nanoparticles for integrin receptor mediated delivery of plasmid DNA
Sadeghpour, H., Khalvati, B., Entezar-Almahdi, E., Savadi, N., Alhashemi, S. H., Raoufi, M., & Dehshahri, A. (2018) · Scientific Reports · doi:10.1038/s41598-018-25277-z · Cited by 45
Selective Targeting of Glioblastoma with EGFRvIII/EGFR Bitargeted Chimeric Antigen Receptor T Cell
Jiang, H., Gao, H., Kong, J., Song, B., Wang, P., Shi, B., Wang, H., & Li, Z. (2018) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-18-0044 · Cited by 44
“Chimeric antigen receptor (CAR)–engineered T (CAR T) cells are a promising strategy for cancer treatment (7).”
Background
Cognizance of Molecular Methods for the Generation of Mutagenic Phage Display Antibody Libraries for Affinity Maturation
Lim, C. C., Choong, Y. S., & Lim, T. S. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20081861 · Cited by 44
Activation of STING inhibits cervical cancer tumor growth through enhancing the anti-tumor immune response
Shi, F., Su, J., Wang, J., Liu, Z., & Wang, T. (2020) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-020-03967-5 · Cited by 44
Therapeutic exosomal vaccine for enhanced cancer immunotherapy by mediating tumor microenvironment
Lv, F., Liu, H., Zhao, G., Zhao, E., Yan, H., Che, R., Yang, X., Zhou, X., Zhang, J., Liang, X., et al. (2021) · iScience · doi:10.1016/j.isci.2021.103639 · Cited by 42
Molecular imaging to enlighten cancer immunotherapies and underlying involved processes
van der Veen, E. L., Bensch, F., Glaudemans, A. W. J. M., Hooge, M. N. L., & de Vries, E. G. E. (2018) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2018.09.007 · Cited by 43
Rationale of Immunotherapy in Hepatocellular Carcinoma and Its Potential Biomarkers
Tai, D. W.-M., Choo, S. P., & Chew, V. (2019) · Cancers · doi:10.3390/cancers11121926 · Cited by 43

Authors: Couzin-Frankel, J.
Corresponding author: Couzin-Frankel, Jennifer
Venue: Science
Publisher: American Association for the Advancement of Science (AAAS)
Published: 2013-12-20
Volume: 342
Issue: 6165
Pages: 1432-1433
ISSN: 0036-8075 (ISSN-L)
1095-9203
DOI: 10.1126/science.342.6165.1432
OpenAlex: W2209812019
Cited by: 2,051
References: 0
Citations by year: 2026: 34 · 2025: 100 · 2024: 133 · 2023: 154 · 2022: 172 · 2021: 215 · 2020: 220 · 2019: 197 · 2018: 206 · 2017: 206 · 2016: 138 · 2015: 169 · 2014: 103 · 2013: 2
FWCI: 73.49
Type: journal article
Language: en
Open access: closed
Locations: Science (publishedVersion)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
Keywords: cancer immunotherapy, tumor immunology, immune checkpoint inhibitors
MeSH terms: Ipilimumab, Antibodies, Antibodies, Monoclonal, Clinical Trials as Topic, Humans, Immunotherapy, Melanoma, Neoplasms, T-Lymphocytes, CTLA-4 Antigen

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Cancer Immunotherapy

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cited by

Related

Metadata

Record

About these checks